Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.40 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.40 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL18586007 | 1.00 | LMNA (0.55) | LMNATSHRALOX12ACHECES2 | |
| Cadaverine Tartrate SCHEMBL28055270 | 0.90 | TSHR (0.56) | LMNATSHRACHECES2CES1 | |
| Toluene SCHEMBL8908638 | 0.85 | LMNA (0.55) | LMNATSHRALOX12ACHECES2 | |
| Cadaverine Tartrate SCHEMBL29071383 | 0.85 | TSHR (0.50) | LMNATSHRACHECES2CES1 | |
| Cadaverine Tartrate SCHEMBL28055271 | 0.85 | TSHR (0.50) | LMNATSHRACHECES2CES1 | |
| Toluene SCHEMBL25341486 | 0.83 | LMNA (0.52) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL27819683 | 0.82 | LMNA (0.58) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL27527983 | 0.82 | LMNA (0.58) | LMNATSHRALOX12ACHECES2 | |
| Cadaverine Tartrate SCHEMBL5550872 | 0.81 | ACHE (0.59) | LMNATSHRACHECES2CES1 | |
| Toluene SCHEMBL7355317 | 0.81 | LMNA (0.73) | LMNATSHRALOX12ACHECES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590602-B | Resolution refining method of racemic citalopram diol | 浙江海森药业股份有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-110590602-A | Resolution refining method of racemic citalopram diol | 浙江海森药业股份有限公司 | 2019-12-20 | — | — | CN | claimed |
| CN-110283109-A | A kind of method of preparation of industrialization racecadotril | 陕西汉江药业集团股份有限公司 | 2019-09-27 | — | — | CN | claimed |
| US-4353918-A | ANTIINFLAMMATORY, ANTIRHEUMATIC | CIBA-GEIGY CORPORATION (US) | 1982-10-12 | — | — | US | claimed |
| CN-114807071-B | Enzymatic preparation method of tofacitinib key intermediate | 中国科学院天津工业生物技术研究所 | 2023-10-20 | — | — | CN | disclosed |
| CN-114807071-A | Enzymatic preparation method of tofacitinib key intermediate | 中国科学院天津工业生物技术研究所 | 2022-07-29 | — | — | CN | disclosed |
| CN-110590602-B | Resolution refining method of racemic citalopram diol | 浙江海森药业股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-110590602-A | Resolution refining method of racemic citalopram diol | 浙江海森药业股份有限公司 | 2019-12-20 | — | — | CN | disclosed |
| CN-108558961-B | Plesiomonas shigelloides O51 serotype O antigen oligosaccharides chemical synthesis process | 江南大学 | 2019-08-06 | — | — | CN | disclosed |
| CN-108558961-A | Plesiomonas shigelloides O51 serotype O antigen oligosaccharides chemical synthesis process | 江南大学 | 2018-09-21 | — | — | CN | disclosed |
| CN-108186391-A | The encapsulating of fragrance and/or flavoring agent in silk-fibroin(s) biomaterial | 塔夫茨大学 | 2018-06-22 | — | — | CN | disclosed |
| CN-104822366-B | Encapsulation of flavors and/or fragrances in silk fibroin biomaterials | 塔夫茨大学 | 2018-03-06 | — | — | CN | disclosed |
| CN-1089261-A | The 1-acylpiperidine compounds | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | CN | disclosed |
| US-5122607-A | RACEMIC AND OPTICALLY ACTIVE OCTAHYDRO-INDOLO(2,3-A) TETRAHYDROPYRANYL (2,3-C) QUINOLIZINE DIESTER DERIVATIVES AND PROCESS FOR PREPARING THE SAME | RICHTER GEDEON VEGYESCZETI GYAR RT. (HU) | 1992-06-16 | — | — | US | disclosed |
| CN-1015707-B | AMIDE DERIVATIVES | ICI PLC (GB) | 1992-03-04 | — | — | CN | disclosed |
| US-5026702-A | Enhances physical performance in animals, effective in lowering blood sugar, reducing body fat and lowering atherogenic lipoproteins | DR. KARL THOMAE, GMBH (DE) | 1991-06-25 | — | — | US | disclosed |
| US-4826838-A | Analgesic carbocyclic and heterocyclic carbonylmethylene-and carbonylmethypipidines and-pyrrolidines | SANDOZ LTD. (CH) | 1989-05-02 | — | — | US | disclosed |
| CN-87105189-A | The production method of amide derivatives | — | 1988-04-06 | — | — | CN | disclosed |
| US-4464535-A | Process for the preparation of eburnamonine derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1984-08-07 | — | — | US | disclosed |
| US-4460580-A | N-Alkylated aminoalcohols and their pharmaceutical compositions useful for the treatment of cardiac insufficiency | CIBA-GEIGY CORPORATION (US) | 1984-07-17 | — | — | US | disclosed |